Lemborexant治疗肝硬化睡眠障碍的随机双盲交叉临床试验
RESTORE试验为前瞻性双盲安慰剂对照交叉研究,纳入82例肝硬化患者随机分入安慰剂组、5 mg Lemborexant组和10 mg Lemborexant组。结果显示5 mg和10 mg Lemborexant均显著降低第2周PSQI评分,5 mg组Stroop测试反应时间改善,10 mg组反应时间轻度但显著增加,肝功能无组间差异。
要点
- Lemborexant 5 mg和10 mg均显著改善肝硬化患者睡眠质量(PSQI降低)。
- 5 mg组Stroop测试反应时间改善,提示认知功能更优;10 mg组反应时间轻度增加。
- 肝功能指标(AST、ALT、总胆红素)在各治疗组间无差异。
核心结论
- Lemborexant对肝硬化患者睡眠问题具有疗效和安全性,尤其5 mg剂量。
研究设计与样本
- RESTORE为前瞻性、双盲、安慰剂对照交叉试验,在Cipto Mangunkusumo国家转诊医院纳入82例肝硬化患者。
- 患者随机分入安慰剂组(n=28)、5 mg Lemborexant组(n=28)和10 mg Lemborexant组(n=26)。
- 疗效通过2周内匹兹堡睡眠质量指数(PSQI)评估;安全性使用EncephalApp Stroop测试评估肝性脑病及肝功能检查(AST、ALT、总胆红素)。
- 交叉后第4周重新评估PSQI以探究反跳性失眠。
主要发现
- 第2周PSQI在5 mg组(MD:-7.0 ± 3.15;p < 0.001)和10 mg组(MD:-8.27 ± 2.68;p < 0.001)均显著降低。
- 5 mg组Stroop测试反应时间改善(MD:-23.5 ± 31.3;p < 0.001),10 mg组反应时间轻度但显著增加(MD:16.7 ± 41.3;p = 0.048)。
- 肝功能在各治疗组间无差异。
- 交叉后分析显示,活性药物组转为安慰剂后PSQI评分持续偏低;初始安慰剂组接受Lemborexant后睡眠改善。
临床怎么用
- 对于肝硬化合并睡眠障碍的患者,Lemborexant 5 mg可作为兼顾睡眠改善与认知安全的可选方案。
- 使用10 mg剂量时需关注Stroop测试反应时间轻度增加所提示的认知影响。
局限性
- 需要更大样本量和更长随访的研究来强化证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIM: No pharmacologic treatment has yet been approved for sleep disturbances in cirrhosis, a high-risk group with substantial prevalence and clinical consequences. Lemborexant has shown efficacy for insomnia, but evidence in cirrhosis is limited. METHODS: Restoring Sleep in End-Stage Liver Disease (RESTORE) is a prospective, double-blind, placebo-controlled, crossover trial of Lemborexant for patients with cirrhosis in Cipto Mangunkusumo National Referral Hospital. We randomized 82 patients into three arms: Placebo (n = 28), 5 mg Lemborexant (n = 28), and 10 mg Lemborexant (n = 26). Efficacy was assessed via Pittsburgh Sleep Quality Index (PSQI) over a 2-week period. Safety was evaluated using the EncephalApp Stroop Test for hepatic encephalopathy and liver function tests including AST, ALT, and total bilirubin. PSQI was reevaluated post-crossover at week 4 to investigate rebound insomnia. RESULTS: Lemborexant significantly reduced PSQI at week 2 in both 5 mg (MD: -7.0 ± 3.15; p < 0.001) and 10 mg groups (MD: -8.27 ± 2.68; p < 0.001), indicating better sleep quality. The 5 mg group showed improved Stroop Test reaction time (MD: -23.5 ± 31.3; p < 0.001), suggesting better cognitive function, whereas 10 mg showed a mild but significant increase in reaction time (MD: 16.7 ± 41.3; p = 0.048). Liver function was not different across treatment groups. Post-crossover analysis showed persistent low PSQI scores in active groups who were switched to placebo. Patients who initially received placebo demonstrated improved sleep after receiving Lemborexant. CONCLUSION: Our study supported the efficacy and safety of Lemborexant, particularly at 5 mg, against sleep problems in cirrhosis. Larger studies with longer follow-up are warranted to strengthen evidence. CLINICALTRIALS: gov: NCT07480096.
引用
- Gani RA, Akbar P, Hasan I, et al. Clinical Trial: Lemborexant Efficacy and Safety in Liver Cirrhosis-Randomized, Double-Blind, Crossover Clinical Trial. Aliment Pharmacol Ther. 2026. PMID: 42414855. doi:10.1111/apt.70811
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。